BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Heidelberg Pharma AG readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Heidelberg Pharma AG's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04879043-3296@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pamlectabart tismanitin: Phase 1/2 readout est. (NCT04879043)
DESCRIPTION:Pamlectabart tismanitin\, phase 1/2\, Multiple Myeloma.\nStudy:
  Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Mu
 ltiple Myeloma\nEstimated primary completion: March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pamlectabart-tismanitin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04879043
URL:https://assetmemo.bio/drug/pamlectabart-tismanitin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
